MA32062B1 - Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments - Google Patents

Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments

Info

Publication number
MA32062B1
MA32062B1 MA33060A MA33060A MA32062B1 MA 32062 B1 MA32062 B1 MA 32062B1 MA 33060 A MA33060 A MA 33060A MA 33060 A MA33060 A MA 33060A MA 32062 B1 MA32062 B1 MA 32062B1
Authority
MA
Morocco
Prior art keywords
trisolium
drugs
produced
salts act
par1
Prior art date
Application number
MA33060A
Other languages
Arabic (ar)
English (en)
Inventor
Uwe Heinelt
Volkmar Wehner
Matthias Herrmann
Karl Schoenafinger
Henning Steinhagen
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32062B1 publication Critical patent/MA32062B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouveaux composés de formule (i) à activité antithrombotique, qui inhibent en particulier le récepteur 1 activé par une protéase (par1), des procédés de production de ces composés et leur utilisation en tant que médicaments.
MA33060A 2008-02-05 2010-08-04 Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments MA32062B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290114 2008-02-05
PCT/EP2009/000407 WO2009097971A1 (fr) 2008-02-05 2009-01-23 Sels de triazolium en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que médicaments

Publications (1)

Publication Number Publication Date
MA32062B1 true MA32062B1 (fr) 2011-02-01

Family

ID=39816936

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33060A MA32062B1 (fr) 2008-02-05 2010-08-04 Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments

Country Status (20)

Country Link
US (2) US8198272B2 (fr)
EP (1) EP2240486B1 (fr)
JP (1) JP5577259B2 (fr)
KR (1) KR20100120139A (fr)
CN (1) CN101981035B (fr)
AU (1) AU2009211888B2 (fr)
BR (1) BRPI0907487A2 (fr)
CA (1) CA2713551C (fr)
CO (1) CO6311103A2 (fr)
ES (1) ES2553588T3 (fr)
HK (1) HK1149012A1 (fr)
IL (1) IL207203A0 (fr)
MA (1) MA32062B1 (fr)
MX (1) MX2010007893A (fr)
MY (1) MY148732A (fr)
NZ (1) NZ587142A (fr)
PL (1) PL2240486T3 (fr)
RU (1) RU2494100C2 (fr)
WO (1) WO2009097971A1 (fr)
ZA (1) ZA201004468B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2240487E (pt) * 2008-02-05 2012-03-08 Sanofi Sa Triazolopiridazinas como inibidores do par1, sua preparação e utilização como produtos farmacêuticos
US8673890B2 (en) 2009-10-29 2014-03-18 Janssen Pharmaceutica Nv 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist
CN102961382B (zh) * 2012-11-28 2014-07-16 玉林师范学院 一种骨肉瘤细胞抑制剂及制备方法
WO2017108737A1 (fr) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. Dérivés de 1-(3-tert-butyl-phényl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tétrahydro-naphthalèn-1-yl)-urée et leur utilisation en tant qu'inhibiteur de p38 mapk
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺
CN115385853B (zh) * 2022-10-17 2024-02-02 山东友道化学有限公司 一种2-肼基-3-氯吡啶的生产方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578464A (en) * 1983-11-22 1986-03-25 Merrell Dow Pharmaceuticals Inc. 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds
LT3200B (en) * 1992-03-18 1995-03-27 Takeda Chemical Industries Ltd Triazolopyridazine methodfor production thereof and use
AU695377B2 (en) * 1994-09-16 1998-08-13 Takeda Chemical Industries Ltd. Triazolopyridazines process and intermediates for their preparation and their use as medicaments
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
CN1243735C (zh) * 2001-04-19 2006-03-01 卫材株式会社 2－亚氨基吡咯烷衍生物
CA2448509A1 (fr) 2001-05-25 2002-12-05 Mochida Pharmaceutical Co., Ltd. Derives de 4-hydroxypiperidine a activite analgesique
US6984653B2 (en) * 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
AR039570A1 (es) 2002-04-16 2005-02-23 Schering Corp Antagonistas de los receptores de trombina
EP2444393A1 (fr) * 2003-02-19 2012-04-25 Eisai R&D Management Co., Ltd. Procédés de production de dérivés de benzamidine cycliques
TW200531688A (en) * 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
EP1813282A4 (fr) 2004-11-09 2011-03-02 Eisai R&D Man Co Ltd Médicament contenant un antagoniste du récepteur de la thrombine au titre de principe actif et destiné au traitement d'angiospasmes causés par une hémorragie sous-arachnoïdienne
BRPI0620292B1 (pt) * 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
DE102006025318A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung
PT2240487E (pt) * 2008-02-05 2012-03-08 Sanofi Sa Triazolopiridazinas como inibidores do par1, sua preparação e utilização como produtos farmacêuticos
DK2242740T3 (da) * 2008-02-05 2013-03-25 Sanofi Sa SF5-derivater som par1-inhibitorer, deres fremstilling og anvendelse som lægemidler
KR20100121612A (ko) * 2008-02-05 2010-11-18 사노피-아벤티스 Ｐａｒ１ 억제제로서의 이미다조피리다진, 이의 제조방법, 및 약제로서의 용도
WO2009126624A1 (fr) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Composés triazolos utiles en tant qu'inhibiteurs de dgat1
US8394823B2 (en) * 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
WO2010009319A2 (fr) * 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres

Also Published As

Publication number Publication date
CN101981035B (zh) 2013-08-28
US8853206B2 (en) 2014-10-07
MY148732A (en) 2013-05-31
HK1149012A1 (en) 2011-09-23
WO2009097971A1 (fr) 2009-08-13
PL2240486T3 (pl) 2016-02-29
US20110034452A1 (en) 2011-02-10
RU2010136941A (ru) 2012-03-20
ES2553588T3 (es) 2015-12-10
EP2240486B1 (fr) 2015-09-09
CO6311103A2 (es) 2011-08-22
US20120208805A1 (en) 2012-08-16
AU2009211888B2 (en) 2013-06-20
CA2713551A1 (fr) 2009-08-13
IL207203A0 (en) 2010-12-30
NZ587142A (en) 2012-04-27
RU2494100C2 (ru) 2013-09-27
ZA201004468B (en) 2011-03-30
KR20100120139A (ko) 2010-11-12
US8198272B2 (en) 2012-06-12
CA2713551C (fr) 2016-06-14
JP2011511017A (ja) 2011-04-07
CN101981035A (zh) 2011-02-23
JP5577259B2 (ja) 2014-08-20
BRPI0907487A2 (pt) 2015-07-14
AU2009211888A1 (en) 2009-08-13
EP2240486A1 (fr) 2010-10-20
MX2010007893A (es) 2010-08-09

Similar Documents

Publication Publication Date Title
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
MA37886A1 (fr) Nouvelles pyridinones bicycliques
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
UY30282A1 (es) Compuestos quimicos
TW200740814A (en) Compounds
MA32062B1 (fr) Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MX2010009462A (es) Derivados de indazol.
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA32479B1 (fr) Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques
EA200970432A1 (ru) 8-сульфонил-1,3,4,8-тетрагидро-2н-[1,4]оксазепино[6,7-e] индольные производные и их использование в качестве 5-нт6 рецепторных лигандов